Loading…

Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease

SH2 domain-containing inositol 5′-phosphatase 2 (SHIP2) is a lipid phosphatase that produce phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2) from phosphatidylinositol 3,4,5-triphosphate (PI(3,4,5)P3), and is involved in many diseases such as neurodegenerative diseases. A recent report demonstrating...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medicinal chemistry 2018-09, Vol.157, p.405-422
Main Authors: Lim, Ji Woong, Kim, Seok Kyu, Choi, Seo Yun, Kim, Dong Hoi, Gadhe, Changdev G., Lee, Hae Nim, Kim, Hyo-Ji, Kim, Jina, Cho, Sung Jin, Hwang, Hayoung, Seong, Jihye, Jeong, Kyu-Sung, Lee, Jae Yeol, Lim, Sang Min, Lee, Jae Wook, Pae, Ae Nim
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c362t-f2fda107004e793ed041f575a54cd7121608a6c4223eb5f88b48b0e824dcb9d63
cites cdi_FETCH-LOGICAL-c362t-f2fda107004e793ed041f575a54cd7121608a6c4223eb5f88b48b0e824dcb9d63
container_end_page 422
container_issue
container_start_page 405
container_title European journal of medicinal chemistry
container_volume 157
creator Lim, Ji Woong
Kim, Seok Kyu
Choi, Seo Yun
Kim, Dong Hoi
Gadhe, Changdev G.
Lee, Hae Nim
Kim, Hyo-Ji
Kim, Jina
Cho, Sung Jin
Hwang, Hayoung
Seong, Jihye
Jeong, Kyu-Sung
Lee, Jae Yeol
Lim, Sang Min
Lee, Jae Wook
Pae, Ae Nim
description SH2 domain-containing inositol 5′-phosphatase 2 (SHIP2) is a lipid phosphatase that produce phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2) from phosphatidylinositol 3,4,5-triphosphate (PI(3,4,5)P3), and is involved in many diseases such as neurodegenerative diseases. A recent report demonstrating that SHIP2 inhibition decreased tau hyperphosphorylation induced by amyloid β and rescued memory impairment in a transgenic Alzheimer's disease mouse model indicates SHIP2 can be a promising therapeutic target for Alzheimer's disease. In the present study, we have developed novel, potent SHIP2 inhibitors by extensive structural elaboration of crizotinib discovered from a high-throughput screening. Our representative compound 43 potently inhibited SHIP2 activity as well as GSK3β activation in HT22 neuronal cells. It was also shown that 43 has favorable physicochemical properties, especially high brain penetration. Considering SHIP2 is one of key signal mediators for tau hyperphosphorylation, our potent SHIP2 inhibitor 43 may function as a promising lead compound for the treatment of Alzheimer's disease. [Display omitted] •SHIP2 has been suggested as a promising therapeutic target for Alzheimer's disease.•We have developed novel, potent SHIP2 inhibitors by extensive structural modification of crizotinib.•The most promising compound 43 potently inhibited SHIP2 activity in HT22 neuronal cells.•43 possessed favorable physicochemical properties including high brain exposure.
doi_str_mv 10.1016/j.ejmech.2018.07.071
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2088292826</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523418306366</els_id><sourcerecordid>2088292826</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-f2fda107004e793ed041f575a54cd7121608a6c4223eb5f88b48b0e824dcb9d63</originalsourceid><addsrcrecordid>eNp9kEGLFDEQhYMo7rj6D0Ry00uPlXS6O3MRlkXdgQUF9RzSSYWpobszJpmB3V9vhlk9Cg_qUF_V4z3G3gpYCxD9x_0a9zO63VqC0GsYqsQzthJDr5tWduo5W4GUbdPJVl2xVznvAaDrAV6yqxYEtGIDKzZtPS6FAjlbKC48Bu4SPcZCC43cY6JTXZwwc5v5IZYK8x932--S07KjkUpMmYeYeNkhLwltmc9IfXMzPe6QZkzvM_eU0WZ8zV4EO2V88zSv2a8vn3_e3jX3375ub2_uG9f2sjRBBm8FDAAKh02LHpQI3dDZTjk_CCl60LZ3qqbDsQtaj0qPgFoq78aN79tr9uHy95Di7yPmYmbKDqfJLhiP2UjQWm6klmdUXVCXYs4Jgzkkmm16MALMuWezN5eezblnA0OVqGfvnhyO44z-39HfYivw6QJgzXkiTCY7wsWhp4SuGB_p_w5_AKTNkSU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2088292826</pqid></control><display><type>article</type><title>Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease</title><source>ScienceDirect Journals</source><creator>Lim, Ji Woong ; Kim, Seok Kyu ; Choi, Seo Yun ; Kim, Dong Hoi ; Gadhe, Changdev G. ; Lee, Hae Nim ; Kim, Hyo-Ji ; Kim, Jina ; Cho, Sung Jin ; Hwang, Hayoung ; Seong, Jihye ; Jeong, Kyu-Sung ; Lee, Jae Yeol ; Lim, Sang Min ; Lee, Jae Wook ; Pae, Ae Nim</creator><creatorcontrib>Lim, Ji Woong ; Kim, Seok Kyu ; Choi, Seo Yun ; Kim, Dong Hoi ; Gadhe, Changdev G. ; Lee, Hae Nim ; Kim, Hyo-Ji ; Kim, Jina ; Cho, Sung Jin ; Hwang, Hayoung ; Seong, Jihye ; Jeong, Kyu-Sung ; Lee, Jae Yeol ; Lim, Sang Min ; Lee, Jae Wook ; Pae, Ae Nim</creatorcontrib><description>SH2 domain-containing inositol 5′-phosphatase 2 (SHIP2) is a lipid phosphatase that produce phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2) from phosphatidylinositol 3,4,5-triphosphate (PI(3,4,5)P3), and is involved in many diseases such as neurodegenerative diseases. A recent report demonstrating that SHIP2 inhibition decreased tau hyperphosphorylation induced by amyloid β and rescued memory impairment in a transgenic Alzheimer's disease mouse model indicates SHIP2 can be a promising therapeutic target for Alzheimer's disease. In the present study, we have developed novel, potent SHIP2 inhibitors by extensive structural elaboration of crizotinib discovered from a high-throughput screening. Our representative compound 43 potently inhibited SHIP2 activity as well as GSK3β activation in HT22 neuronal cells. It was also shown that 43 has favorable physicochemical properties, especially high brain penetration. Considering SHIP2 is one of key signal mediators for tau hyperphosphorylation, our potent SHIP2 inhibitor 43 may function as a promising lead compound for the treatment of Alzheimer's disease. [Display omitted] •SHIP2 has been suggested as a promising therapeutic target for Alzheimer's disease.•We have developed novel, potent SHIP2 inhibitors by extensive structural modification of crizotinib.•The most promising compound 43 potently inhibited SHIP2 activity in HT22 neuronal cells.•43 possessed favorable physicochemical properties including high brain exposure.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2018.07.071</identifier><identifier>PMID: 30103190</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Alzheimer's disease ; Crizotinib ; SH2 domain-containing inositol 5′-phosphatase 2 ; Tau</subject><ispartof>European journal of medicinal chemistry, 2018-09, Vol.157, p.405-422</ispartof><rights>2018 Elsevier Masson SAS</rights><rights>Copyright © 2018 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-f2fda107004e793ed041f575a54cd7121608a6c4223eb5f88b48b0e824dcb9d63</citedby><cites>FETCH-LOGICAL-c362t-f2fda107004e793ed041f575a54cd7121608a6c4223eb5f88b48b0e824dcb9d63</cites><orcidid>0000-0003-0419-8950 ; 0000-0002-3678-8253 ; 0000-0002-4786-8830 ; 0000-0001-6622-6692</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30103190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lim, Ji Woong</creatorcontrib><creatorcontrib>Kim, Seok Kyu</creatorcontrib><creatorcontrib>Choi, Seo Yun</creatorcontrib><creatorcontrib>Kim, Dong Hoi</creatorcontrib><creatorcontrib>Gadhe, Changdev G.</creatorcontrib><creatorcontrib>Lee, Hae Nim</creatorcontrib><creatorcontrib>Kim, Hyo-Ji</creatorcontrib><creatorcontrib>Kim, Jina</creatorcontrib><creatorcontrib>Cho, Sung Jin</creatorcontrib><creatorcontrib>Hwang, Hayoung</creatorcontrib><creatorcontrib>Seong, Jihye</creatorcontrib><creatorcontrib>Jeong, Kyu-Sung</creatorcontrib><creatorcontrib>Lee, Jae Yeol</creatorcontrib><creatorcontrib>Lim, Sang Min</creatorcontrib><creatorcontrib>Lee, Jae Wook</creatorcontrib><creatorcontrib>Pae, Ae Nim</creatorcontrib><title>Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>SH2 domain-containing inositol 5′-phosphatase 2 (SHIP2) is a lipid phosphatase that produce phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2) from phosphatidylinositol 3,4,5-triphosphate (PI(3,4,5)P3), and is involved in many diseases such as neurodegenerative diseases. A recent report demonstrating that SHIP2 inhibition decreased tau hyperphosphorylation induced by amyloid β and rescued memory impairment in a transgenic Alzheimer's disease mouse model indicates SHIP2 can be a promising therapeutic target for Alzheimer's disease. In the present study, we have developed novel, potent SHIP2 inhibitors by extensive structural elaboration of crizotinib discovered from a high-throughput screening. Our representative compound 43 potently inhibited SHIP2 activity as well as GSK3β activation in HT22 neuronal cells. It was also shown that 43 has favorable physicochemical properties, especially high brain penetration. Considering SHIP2 is one of key signal mediators for tau hyperphosphorylation, our potent SHIP2 inhibitor 43 may function as a promising lead compound for the treatment of Alzheimer's disease. [Display omitted] •SHIP2 has been suggested as a promising therapeutic target for Alzheimer's disease.•We have developed novel, potent SHIP2 inhibitors by extensive structural modification of crizotinib.•The most promising compound 43 potently inhibited SHIP2 activity in HT22 neuronal cells.•43 possessed favorable physicochemical properties including high brain exposure.</description><subject>Alzheimer's disease</subject><subject>Crizotinib</subject><subject>SH2 domain-containing inositol 5′-phosphatase 2</subject><subject>Tau</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kEGLFDEQhYMo7rj6D0Ry00uPlXS6O3MRlkXdgQUF9RzSSYWpobszJpmB3V9vhlk9Cg_qUF_V4z3G3gpYCxD9x_0a9zO63VqC0GsYqsQzthJDr5tWduo5W4GUbdPJVl2xVznvAaDrAV6yqxYEtGIDKzZtPS6FAjlbKC48Bu4SPcZCC43cY6JTXZwwc5v5IZYK8x932--S07KjkUpMmYeYeNkhLwltmc9IfXMzPe6QZkzvM_eU0WZ8zV4EO2V88zSv2a8vn3_e3jX3375ub2_uG9f2sjRBBm8FDAAKh02LHpQI3dDZTjk_CCl60LZ3qqbDsQtaj0qPgFoq78aN79tr9uHy95Di7yPmYmbKDqfJLhiP2UjQWm6klmdUXVCXYs4Jgzkkmm16MALMuWezN5eezblnA0OVqGfvnhyO44z-39HfYivw6QJgzXkiTCY7wsWhp4SuGB_p_w5_AKTNkSU</recordid><startdate>20180905</startdate><enddate>20180905</enddate><creator>Lim, Ji Woong</creator><creator>Kim, Seok Kyu</creator><creator>Choi, Seo Yun</creator><creator>Kim, Dong Hoi</creator><creator>Gadhe, Changdev G.</creator><creator>Lee, Hae Nim</creator><creator>Kim, Hyo-Ji</creator><creator>Kim, Jina</creator><creator>Cho, Sung Jin</creator><creator>Hwang, Hayoung</creator><creator>Seong, Jihye</creator><creator>Jeong, Kyu-Sung</creator><creator>Lee, Jae Yeol</creator><creator>Lim, Sang Min</creator><creator>Lee, Jae Wook</creator><creator>Pae, Ae Nim</creator><general>Elsevier Masson SAS</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0419-8950</orcidid><orcidid>https://orcid.org/0000-0002-3678-8253</orcidid><orcidid>https://orcid.org/0000-0002-4786-8830</orcidid><orcidid>https://orcid.org/0000-0001-6622-6692</orcidid></search><sort><creationdate>20180905</creationdate><title>Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease</title><author>Lim, Ji Woong ; Kim, Seok Kyu ; Choi, Seo Yun ; Kim, Dong Hoi ; Gadhe, Changdev G. ; Lee, Hae Nim ; Kim, Hyo-Ji ; Kim, Jina ; Cho, Sung Jin ; Hwang, Hayoung ; Seong, Jihye ; Jeong, Kyu-Sung ; Lee, Jae Yeol ; Lim, Sang Min ; Lee, Jae Wook ; Pae, Ae Nim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-f2fda107004e793ed041f575a54cd7121608a6c4223eb5f88b48b0e824dcb9d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Alzheimer's disease</topic><topic>Crizotinib</topic><topic>SH2 domain-containing inositol 5′-phosphatase 2</topic><topic>Tau</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lim, Ji Woong</creatorcontrib><creatorcontrib>Kim, Seok Kyu</creatorcontrib><creatorcontrib>Choi, Seo Yun</creatorcontrib><creatorcontrib>Kim, Dong Hoi</creatorcontrib><creatorcontrib>Gadhe, Changdev G.</creatorcontrib><creatorcontrib>Lee, Hae Nim</creatorcontrib><creatorcontrib>Kim, Hyo-Ji</creatorcontrib><creatorcontrib>Kim, Jina</creatorcontrib><creatorcontrib>Cho, Sung Jin</creatorcontrib><creatorcontrib>Hwang, Hayoung</creatorcontrib><creatorcontrib>Seong, Jihye</creatorcontrib><creatorcontrib>Jeong, Kyu-Sung</creatorcontrib><creatorcontrib>Lee, Jae Yeol</creatorcontrib><creatorcontrib>Lim, Sang Min</creatorcontrib><creatorcontrib>Lee, Jae Wook</creatorcontrib><creatorcontrib>Pae, Ae Nim</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lim, Ji Woong</au><au>Kim, Seok Kyu</au><au>Choi, Seo Yun</au><au>Kim, Dong Hoi</au><au>Gadhe, Changdev G.</au><au>Lee, Hae Nim</au><au>Kim, Hyo-Ji</au><au>Kim, Jina</au><au>Cho, Sung Jin</au><au>Hwang, Hayoung</au><au>Seong, Jihye</au><au>Jeong, Kyu-Sung</au><au>Lee, Jae Yeol</au><au>Lim, Sang Min</au><au>Lee, Jae Wook</au><au>Pae, Ae Nim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2018-09-05</date><risdate>2018</risdate><volume>157</volume><spage>405</spage><epage>422</epage><pages>405-422</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>SH2 domain-containing inositol 5′-phosphatase 2 (SHIP2) is a lipid phosphatase that produce phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2) from phosphatidylinositol 3,4,5-triphosphate (PI(3,4,5)P3), and is involved in many diseases such as neurodegenerative diseases. A recent report demonstrating that SHIP2 inhibition decreased tau hyperphosphorylation induced by amyloid β and rescued memory impairment in a transgenic Alzheimer's disease mouse model indicates SHIP2 can be a promising therapeutic target for Alzheimer's disease. In the present study, we have developed novel, potent SHIP2 inhibitors by extensive structural elaboration of crizotinib discovered from a high-throughput screening. Our representative compound 43 potently inhibited SHIP2 activity as well as GSK3β activation in HT22 neuronal cells. It was also shown that 43 has favorable physicochemical properties, especially high brain penetration. Considering SHIP2 is one of key signal mediators for tau hyperphosphorylation, our potent SHIP2 inhibitor 43 may function as a promising lead compound for the treatment of Alzheimer's disease. [Display omitted] •SHIP2 has been suggested as a promising therapeutic target for Alzheimer's disease.•We have developed novel, potent SHIP2 inhibitors by extensive structural modification of crizotinib.•The most promising compound 43 potently inhibited SHIP2 activity in HT22 neuronal cells.•43 possessed favorable physicochemical properties including high brain exposure.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>30103190</pmid><doi>10.1016/j.ejmech.2018.07.071</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0003-0419-8950</orcidid><orcidid>https://orcid.org/0000-0002-3678-8253</orcidid><orcidid>https://orcid.org/0000-0002-4786-8830</orcidid><orcidid>https://orcid.org/0000-0001-6622-6692</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0223-5234
ispartof European journal of medicinal chemistry, 2018-09, Vol.157, p.405-422
issn 0223-5234
1768-3254
language eng
recordid cdi_proquest_miscellaneous_2088292826
source ScienceDirect Journals
subjects Alzheimer's disease
Crizotinib
SH2 domain-containing inositol 5′-phosphatase 2
Tau
title Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A59%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20crizotinib%20derivatives%20as%20potent%20SHIP2%20inhibitors%20for%20the%20treatment%20of%20Alzheimer's%20disease&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Lim,%20Ji%20Woong&rft.date=2018-09-05&rft.volume=157&rft.spage=405&rft.epage=422&rft.pages=405-422&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2018.07.071&rft_dat=%3Cproquest_cross%3E2088292826%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c362t-f2fda107004e793ed041f575a54cd7121608a6c4223eb5f88b48b0e824dcb9d63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2088292826&rft_id=info:pmid/30103190&rfr_iscdi=true